Bart J. F. van den Bemt

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten et al. · BMJ · 2015 · 181 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen et al. · Arthritis & Rheumatology · 2017 · 164 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs

Bart J. F. van den Bemt, F.H.J. van den Hoogen, B. Benraad et al. · The Journal of Rheumatology · 2009 · 142 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

Aatke van der Maas, Wietske Kievit, Bart J. F. van den Bemt et al. · Annals of the Rheumatic Diseases · 2012 · 102 citations

Medicine, Clinical Sciences, Pharmacotherapy +16

European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper

Tobias Dreischulte, Bart J. F. van den Bemt, Stéphane Steurbaut · International Journal of Clinical Pharmacy · 2022 · 102 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacy Practice +8